STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

electroCore to Announce Third Quarter September 30, 2025 Financial Results on Wednesday, November 5, 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

electroCore (Nasdaq: ECOR) will report third quarter results for the period ended September 30, 2025 after market close on Wednesday, November 5, 2025. Management will host a results webinar on November 5, 2025 at 4:30 PM EST to review the financial results and answer questions.

Investors can join via dial-in (646) 931-3860, Webinar ID 822 9598 1338, passcode 454695, or register using the provided registration link to participate and ask questions.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction 1 Alert

+1.45% News Effect

On the day this news was published, ECOR gained 1.45%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

ROCKAWAY, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the third quarter ended September 30, 2025, after the close of the market on Wednesday, November 5, 2025.

Management will host a webinar at 4:30 PM EST to review the financial results and answer questions. Investors can access the webinar using the details below:

Wednesday, November 5, 4:30 PM EST
Dial-In: (646) 931-3860
Webinar ID: 822 9598 1338
Passcode: 454695
Registration Link: Click here to participate and ask questions on the call.

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.

For more information, visit www.electrocore.com.

Contact
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com


FAQ

When will electroCore (ECOR) report Q3 2025 results?

electroCore will report third quarter results for the period ended September 30, 2025 after market close on November 5, 2025.

What time is the electroCore (ECOR) Q3 2025 webinar and how can I join?

The webinar is scheduled for 4:30 PM EST on November 5, 2025; join via dial-in (646) 931-3860 or Webinar ID 822 9598 1338 with passcode 454695.

How can investors register to ask questions on the electroCore (ECOR) November 5, 2025 call?

Investors can register using the provided registration link to participate and submit questions during the webinar.

Will electroCore (ECOR) management answer questions during the Q3 2025 webcast?

Yes; management will review results and answer questions during the 4:30 PM EST webinar on November 5, 2025.

What are the dial-in details for the electroCore (ECOR) Q3 2025 results call?

Dial-in: (646) 931-3860; Webinar ID: 822 9598 1338; Passcode: 454695.
Electrocore

NASDAQ:ECOR

ECOR Rankings

ECOR Latest News

ECOR Latest SEC Filings

ECOR Stock Data

38.54M
5.14M
37.28%
15.51%
5.96%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
ROCKAWAY